- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal, Monotherapy: Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations. (Pubmed Central) - Jul 4, 2020 Due to the diversity of adaptive responses to monotherapy, monitoring the response to treatment in patients is critical to understand the path that leads to resistance and to guide the optimal therapeutic drug combinations in the clinical setting. We envisage that applying such a rationale-based therapeutic strategy will improve treatment efficacy in HNC patients.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, Journal: Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02). (Pubmed Central) - Jul 4, 2020 P2 This prospective biomarker design study has important clinical implications because many prospective clinical trials are designed with the hypothesis that BRAF mutation per se and MEK and PIK3CA downstream pathways are critical for colorectal tumor survival. The results lead to the question of whether these pathways should be considered as passengers instead of drivers.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Review, Journal: Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC). (Pubmed Central) - Jul 3, 2020 In so far as the clinical data of tumor sidedness is concerned, very few reviews have discussed the clinical implications of sidedness in heavily pre-treated metastatic colorectal cancer (second and subsequent lines of therapy in metastatic disease). This review aims to fill the current gap in this setting.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. (Pubmed Central) - Jul 1, 2020 Other alterations, such as EGFR T790 M, are responsive to osimertinib, while the EGFR C797S alteration seen in osimertinib resistance demonstrates preclinical sensitivity to combined brigatinib and cetuximab. These observations indicate that clinical resistance can be overcome by utilizing advanced genomic interrogation coupled with computer modeling.
- |||||||||| Trial completion, Trial completion date, Trial primary completion date, Combination therapy: Bevacizumab in Multiple Phase I Combinations (clinicaltrials.gov) - Jun 30, 2020
P1, N=343, Completed, These observations indicate that clinical resistance can be overcome by utilizing advanced genomic interrogation coupled with computer modeling. Active, not recruiting --> Completed | Trial completion date: Oct 2020 --> Apr 2020 | Trial primary completion date: Oct 2020 --> Apr 2020
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Red Meat Allergies after Lone Star Tick (Amblyomma americanum) Bites. (Pubmed Central) - Jun 28, 2020 Following confirmation by challenge testing, patients with red meat allergies should avoid red meats, foods containing gelatin, and intravenous immunotherapy with monoclonal antibodies such as cetuximab and infliximab produced in SP2/0 mouse cell lines. Red meat allergy after tick bites represents an emerging threat from tick bites in addition to infectious diseases.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Boosting of the enhanced permeability and retention effect with nanocapsules improves the therapeutic effects of cetuximab. (Pubmed Central) - Jun 27, 2020 The nanocapsule-based delivery system efficiently delivered tAbs to tumor tissues and released them to boost the EPR effect, which facilitated further tumor accumulation of the tAbs. This novel self-augmentation of the EPR effect facilitated by the biological characteristics of tAbs and nanotechnology contributed to the improvement of the therapeutic effect of tAbs, and stimulated new ideas for antibody-based tumor therapy.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Enrollment open, Surgery: SULTAN: Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (clinicaltrials.gov) - Jun 25, 2020 P2, N=140, Recruiting, Acquired resistance, in patients with initial treatment benefit, is mainly explained by polyclonal emergence of RAS, BRAF and EGFR mutations in ctDNA. Suspended --> Recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Mammalian Meat Allergy – A Novel Presentation and a Review of the Literature () - Jun 20, 2020 - Abstract #AADVMX2020AAD-VMX_184; Severe anaphylaxis has also been seen following cetuximab treatment, as α-gal residues are present on the Fab segments of the monoclonal antibody...To our knowledge, this is the first reported case of MMA presenting as exfoliative erythroderma. We review the relevant literature and the postulated pathogenesis behind this presentation.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, Combination therapy: Monomer preference of EGFR tyrosine kinase inhibitors influences the synergistic efficacy of combination therapy with cetuximab. (Pubmed Central) - Jun 19, 2020 In this study, we evaluated the effects of multiple EGFR-TKIs on the EGFR monomer-dimer equilibrium by inducing dimerization-impairing mutations in cells expressing EGFR Interestingly, we found that afatinib and dacomitinib exhibit a monomer preference: cells expressing dimerization-impaired EGFR mutants exhibited increased sensitivity to afatinib and dacomitinib relative to those with dimerization-competent EGFR mutants...In addition, we propose the novel concept that monomer-dimer equilibrium is an important factor in determining EGFR-TKI efficacy. These findings provide novel insights into treatment strategies for EGFR-TKI-refractory non-small cell lung cancer.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Metallopeptidase Inhibitor 1 (TIMP-1) promotes receptor tyrosine kinase c-Kit signaling in colorectal cancer. (Pubmed Central) - Jun 19, 2020 Different types of treatment are available for patients with advanced metastatic colorectal cancer, including targeted biological agents, such as cetuximab, a monoclonal antibody that targets EGFR...In addition, TIMP-1 inhibited c-Kit shedding in CRC cells grown in the presence of exogenous TIMP-1. Given the regulatory roles that c-Kit plays in cell proliferation and migration, and the realization that c-Kit is an important oncogene in CRC, it is likely that some of the biological effects of TIMP-1 overexpression in CRC may be exerted through its effect on c-Kit signaling.
- |||||||||| cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) (clinicaltrials.gov) - Jun 19, 2020 P2, N=96, Active, not recruiting, This well-tolerated combination demonstrated promising activity in cetuximab-resistant, advanced HNSCC. Recruiting --> Active, not recruiting | Trial completion date: Oct 2030 --> Dec 2029 | Trial primary completion date: Mar 2021 --> Dec 2019
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, IO Biomarker: Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma. (Pubmed Central) - Jun 18, 2020 Recruiting --> Active, not recruiting | Trial completion date: Oct 2030 --> Dec 2029 | Trial primary completion date: Mar 2021 --> Dec 2019 Altogether, these results suggest that IL-1α in combination with cetuximab can induce a T cell-dependent anti-tumor immune response and may represent a novel immunotherapeutic strategy for EGFR-positive HNSCCs.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, irinotecan / Generic mfg.
Review, Journal: Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. (Pubmed Central) - Jun 18, 2020 Our working hypothesis suggests that the CALGB/SWOG 80405 and FIRE-3 studies are complementary rather than discrepant, and it provides an explanation for their opposing interpretations. In conclusion, proper interpretation of the CALGB/SWOG 80405 and FIRE-3 results requires an in-depth examination of the complex interplay, not only between the targeted biological agents and chemotherapeutic drugs, but also between therapies and the tumour biology and microenvironment, for each line of treatment.
- |||||||||| Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Palbociclib: a new partner for cetuximab? (Pubmed Central) - Jun 18, 2020 In conclusion, proper interpretation of the CALGB/SWOG 80405 and FIRE-3 results requires an in-depth examination of the complex interplay, not only between the targeted biological agents and chemotherapeutic drugs, but also between therapies and the tumour biology and microenvironment, for each line of treatment. No abstract available
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial completion date, Trial primary completion date, Metastases: Cetuximab Rechallenge Study (clinicaltrials.gov) - Jun 18, 2020 P2, N=17, Completed, No abstract available Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Apr 2020 | Trial primary completion date: Dec 2021 --> Apr 2020
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, paclitaxel / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
Clinical, Journal: A large single hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents. (Pubmed Central) - Jun 15, 2020 P2YRs mediate HNSCC cell responses to extracellular nucleotides and genetic or pharmacological blockade of P2YR signaling attenuates tumor cell proliferation and tumorigenesis, suggesting that the P2YR represents a novel therapeutic target in HNSCC. This experience allows us to describe general management plans, as well as specific patient phenotypic patterns, predictors for reactions and risk considerations which need a tailored approach (taking into account the three prominent drug categories: platins, taxanes and biologicals).
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Primary Tumor Resection for Stage IV Colorectal Cancer in the Era of Targeted Chemotherapy. (Pubmed Central) - Jun 15, 2020 This experience allows us to describe general management plans, as well as specific patient phenotypic patterns, predictors for reactions and risk considerations which need a tailored approach (taking into account the three prominent drug categories: platins, taxanes and biologicals). All three analyses revealed that, in the current era of chemotherapy with target agents, primary tumor resection was only marginally influential and did not significantly improve overall survival over chemotherapy alone.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro. (Pubmed Central) - Jun 14, 2020 Taken together, in our current study we have developed a PEGylated targeted nanoconjugate ACG44P1000 that showed enhanced selectivity towards pancreatic cancer cells and pancreatic stellate cells, among others, for gemcitabine delivery. We will investigate the ability of these optimized conjugates to inhibit desmoplasia and tumor growth in vivo in our future studies.
- |||||||||| cisplatin / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Recurrent cisplatin hypersensitivity reaction after first exposure: A case report. (Pubmed Central) - Jun 12, 2020 Skin allergy testing has limited sensitivity for platinum-based chemotherapy and caution should be exercised in weighing risk and benefits of re-exposure. Although rare, cisplatin hypersensitivity can present after first exposure.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Zelboraf (vemurafenib) / Roche
Trial completion, Trial completion date, Metastases: S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 11, 2020 P2, N=106, Completed, Although rare, cisplatin hypersensitivity can present after first exposure. Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Jun 2020
|